[18F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience.
Sign Up to like & getrecommendations! Published in 2018 at "European urology focus"
DOI: 10.1016/j.euf.2016.10.002
Abstract: An ongoing prospective study is acquiring preoperative imaging data for men with prostate cancer (PCa) using the molecular imaging agent [18F]-DCFPyL targeted against prostate-specific membrane antigen (PSMA). To date, six men (of a planned accrual… read more here.
Keywords: prostate; 18f dcfpyl; pathology; positron emission ... See more keywords
Role of 18F-DCFPyL PET/CT in patients with suspected prostate cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Hellenic journal of nuclear medicine"
DOI: 10.1967/s002449912431
Abstract: OBJECTIVE Fluorine-18-2-(3-{1-carboxy-5-[(6-18F-flfluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL), a novel positron emission tomography/computed tomography (PET/CT) radiotracer that binds to the prostate specific membrane antigen (PSMA), is increasingly used for biochemically recurrent prostate cancer diagnostics. However, the 18F-DCFPyL characteristics of… read more here.
Keywords: prostate cancer; dcfpyl; dcfpyl pet; 18f dcfpyl ... See more keywords